The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

Michelle Tarver, of the FDA's Center for Devices and Radiological Health, said: "Today's clearance is an important step for ...

Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.

Alzheimer’s researcher Donald Weaver tells The Conversation Weekly podcast what he’s learnt during more than 30 years of ...

As researchers work to improve treatment of Alzheimer's disease, new research by UCLA Health identified a candidate drug that ...

TREATING cold sores with anti-viral medicines could slash the risk of Alzheimer’s disease by 17 per cent, research suggests. Previous studies have found that the herpes simplex virus – ...

The very first blood test for Alzheimer's disease detection has been green-lit by the US Food and Drug Administration (FDA), ...

HSV-1 infection may be linked to the risk for Alzheimer’s disease, but antiviral treatment may be protective, a large ...

A drug that's been found to slow the progress ... it had been TGA-approved was huge news for the dementia community, especially after a similar treatment called Lecanemab was refused registration ...

Catching the virus that causes cold sores almost doubles the risk of developing Alzheimer's - but treatment slashes the odds, ...

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal ...

The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.